The median follow-up was 38.8 months in the phase II-treated patient

 The median follow-up was 38.8 months in the phase II-treated patient 

cohort (n=55). The OS rate at 36.0 months was 47.1%, with a median OS of 26.0 months among all treated phase II patients and 38.9 months in patients with CR or CR with incomplete hematologic recovery.

Management stated that the continued durable response and significant improvement in survival indicated by these new data bode well for Tecartus as a new standard of care for adult patients living with this aggressive form of leukemia.

Gilead’s stock has gained 37.9% in the past year against the industry's decline of 10.1%.